Baseline demographics of the Valsartan Heart Failure Trial

European Journal of Heart Failure

Volumn 2, Issue 4, 2000, Pages 439-446

  Cohn, Jay N ^a   Tognoni, Gianni ^b   Glazer, Robert ^c   Spormann, Dirk ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin receptor blocker; Baseline demographics; Clinical trial; Heart failure; Valsartan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITOXIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; VALSARTAN;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; SEX FACTORS; TETRAZOLES; VALINE;

EID: 0034535686     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(00)00130-6     Document Type: Article

References (19)

1. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
2. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
4. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
5. Consensus recommendations for the management of chronic heart failure
6. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
7. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
8. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
9. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study
10. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?
11. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
12. Survival after the onset of congestive heart failure in Framingham Heart Study subjects
13. Relation between gender, etiology and survival in patients with symptomatic heart failure
14. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])
15. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
16. The epidemiology of heart failure: The Framingham Study
17. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study
18. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure